Skip to main content
Article thumbnail
Location of Repository

Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides

By M Mastorikou, B Mackness, Y Liu and M Mackness
Topics: Original Articles
Publisher: Blackwell Publishing Ltd
OAI identifier: oai:pubmedcentral.nih.gov:2659363
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2004). Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with Type 2 diabetes. Metabolism
    2. (2006). Defective metabolism of oxidised-phospholipids by high-density lipoprotein from people with Type 2 diabetes. Diabetes
    3. (2003). Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia
    4. (2001). Effect of glycation of high-density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol
    5. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letts
    6. (1999). for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.
    7. Glycation impairs high-density lipoprotein function. Diabetologia
    8. (1996). High density lipoproteins and coronary heart disease. Atherosclerosis
    9. (2000). How HDL protects against the effects of lipid peroxidation. Curr Opinion Lipidol
    10. Human serum paraoxonase 1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscl Thromb Vasc Biol
    11. (1998). Human serum paraoxonase. Gen Pharmac
    12. (2002). Is the oxidative modifications hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date reflect the hypothesis? Circulation
    13. (1992). Lipoprotein separation and analysis for clinical studies. In:
    14. (2000). Low paraoxonase activity in Type II diabetes complicated by retinopathy. Clin Sci
    15. (2003). Low paraoxonase activity predicts coronary events in the Caerphilly prospective Study. Circulation
    16. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature
    17. (1991). Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.
    18. (1992). Nonenzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis
    19. (1996). Oxidised lipoproteins and atherosclerosis.
    20. (1998). Oxidised low-density lipoprotein: a two-faced Janus in coronary artery disease? Biochem Pharmacol
    21. (2004). Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. BBRC
    22. (1991). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.
    23. (2005). Paraoxonase-1 (PON1) genotype and activity and in vivo oxidised, plasma low-density lipoprotein in Type II diabetes. Clin Sci (Lond)
    24. (2006). Paraoxonase1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein deficient serum: relevance to diabetes. Atherosclerosis
    25. (1993). Protection of low-density lipoprotein against oxidative modification by highdensity lipoprotein associated paraoxonase. Atherosclerosis
    26. (1995). Protective effect of high-density lipoprotein associated paraoxonase—inhibition of the biological activity of minimally oxidised low-density lipoprotein.
    27. (2004). Protective effect of paraoxonase activity in high density lipoproteins against erythrocyte membrane peroxidation: a comparison between healthy subjects and Type 1 diabetic patients.
    28. (1980). Report of the WHO Expert Committee on Diabetes Mellitus.
    29. (1998). Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis
    30. (2001). Serum paraoxonase is reduced in Type 1 diabetic patients compared to non-diabetic, first-degree relatives: influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis
    31. (2006). The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, stimulation of lipo-lactonase and macrophage cholesterol efflux.
    32. (1996). The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.